资源描述：
《New_Cancer_Medicines_in_Development__Part_3_.13》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、PAGE27/AUGUST25,2005NewCancerMedicinesinDevelopment(Part3)Thistable,thethirdofseveralparts(Part1wasintheJuly10issueandPart2cer,26forkidneycancer,52forleukemia,13forlivercancer,51forlymphomas,20wasintheJuly25issue),isadaptedandexcerptedfromthelatestformyeloma,threeforne
2、uroblastoma,21forovariancancer,25forpancreaticcan-PharmaceuticalResearchandManufacturersofAmericasurveyofMedicinesincer,eightforsarcoma,39forskincancer,85forvarioussolidtumors,15forstom-DevelopmentforCancer.Ofthe399medicinesindevelopmentbytheNationalachcancer,24forcanc
3、er-relatedconditions,and49forotherandunspecifiedcan-CancerInstituteand178pharmaceuticalandbiotechnologycompanies,62areforcers.Thechartshowsthenameofeachproduct,thecompany/organizationlungcancer,49forbreastcancer,50forprostatecancer,35forcoloncancer,sixforinvolved,thein
4、dication,andthedevelopmentstatusasofthetimeofthereportbladdercancer,25forbraincancer,13forcervicalcancer,15forheadandneckcan-thisspring,andacontacttelephonenumbertorequestfurtherinformation.LungCancer(continuedfromJuly25issue)ProductNameSponsorIndicationDevelopmentStat
5、usProductNameSponsorIndicationDevelopmentStatusCMD-193WyethNSCLC(seealsobreast)PhaseIhuN901-DM1ImmunoGenSCLCPhaseI/IIPharmaceuticals(800)934-5556Cambridge,MA(seealsomyeloma)(617)995-2500Collegeville,PAHycamtin®GlaxoSmithKlineSCLC(oral,2nd-linePhaseIIICP-547,632(anti-OS
6、IPhaseIItopotecanPhiladelphia,PAtreatment)(seealsobrain,(888)825-5249VEGF-tyrosinePharmaceuticals(860)732-7920Rsch.Triangleovarian)kinase)Melville,NYPark,NCPfizerIMC-BEC2ImcloneSystemsSCLCPhaseIIINewYork,NY(cancervaccine)NewYork,NY(212)645-1405Dacogen™NationalCancerNSC
7、LC,pleuralcancer,PhaseIINGN225IntrogenSCLC(seealsobreast)PhaseI/IIdecitabineInstitutepulmonarycancer(seeNCITrial(p53vaccine)Therapeutics(512)708-9310Bethesda,MDalsoleukemia,solid(800)4-CANCERAustin,TXMGIPharmatumors,other)Minneapolis,MNINGN401IntrogenPhaseISuperGen(FUS
8、-1)Therapeutics(512)708-9310Dublin,CAAustin,TXIressa®AstraZenecaNSCLC(seealsobreast,PhaseII/IIIdepsipeptideNationalCa
